The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir ...

Scientists say the drug stops the virus from replicating inside cells. The landmark deal to provide cheaper antiretroviral ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

Cheap generic versions of a groundbreaking HIV-prevention jab should be available in more than 100 countries from 2027, ...

Gilead's groundbreaking HIV prevention drug will soon be available at a fraction of its U.S. price in over 100 countries, ...

Global health groups will provide backing for two generic manufacturers to produce and distribute a low-cost version of a new ...

HIV (human immunodeficiency virus) remains a significant global health challenge, affecting millions of people worldwide. While advancements in medical science have led to better management of the ...

Avoidable HIV infections and net health care costs would rise if coverage of pre-exposure prophylaxis (PrEP) were to be reduced even a moderate amount, according to a study published in JAMA Network ...

Lenacapavir is a long-acting HIV medication known as a capsid inhibitor. It works by blocking the virus's protective shell, ...

Pre-exposure prophylaxis (PrEP) is a medication regimen that is used to protect at-risk populations from HIV infection. The FDA approved the drug TRUVADA ...

Most transfeminine people support OTC access to PrEP for HIV prevention as means to eliminate burden and costs of clinical visits and laboratory testing.

Stigma and lack of support hinder PrEP use among Black women; clinician bias and discrimination worsen disparities.